PA8656601A1 - Nuevos usos para los agonistas beta de estrogenos - Google Patents

Nuevos usos para los agonistas beta de estrogenos

Info

Publication number
PA8656601A1
PA8656601A1 PA20058656601A PA8656601A PA8656601A1 PA 8656601 A1 PA8656601 A1 PA 8656601A1 PA 20058656601 A PA20058656601 A PA 20058656601A PA 8656601 A PA8656601 A PA 8656601A PA 8656601 A1 PA8656601 A1 PA 8656601A1
Authority
PA
Panama
Prior art keywords
beta
new uses
estrogen agonists
estrogen
agonists
Prior art date
Application number
PA20058656601A
Other languages
English (en)
Spanish (es)
Inventor
Mark Day
Heather A Harris
Original Assignee
Wyeth Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Wyeth filed Critical Wyeth Wyeth
Publication of PA8656601A1 publication Critical patent/PA8656601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PA20058656601A 2004-12-17 2005-12-15 Nuevos usos para los agonistas beta de estrogenos PA8656601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63714404P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
PA8656601A1 true PA8656601A1 (es) 2006-12-07

Family

ID=36143266

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058656601A PA8656601A1 (es) 2004-12-17 2005-12-15 Nuevos usos para los agonistas beta de estrogenos

Country Status (20)

Country Link
US (1) US20060135574A1 (cg-RX-API-DMAC7.html)
EP (1) EP1824478A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008524236A (cg-RX-API-DMAC7.html)
KR (1) KR20070086329A (cg-RX-API-DMAC7.html)
CN (1) CN101321524A (cg-RX-API-DMAC7.html)
AR (1) AR051844A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005316561A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519111A2 (cg-RX-API-DMAC7.html)
CA (1) CA2590258A1 (cg-RX-API-DMAC7.html)
GT (1) GT200500370A (cg-RX-API-DMAC7.html)
IL (1) IL183604A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007007347A (cg-RX-API-DMAC7.html)
NI (1) NI200700152A (cg-RX-API-DMAC7.html)
NO (1) NO20072658L (cg-RX-API-DMAC7.html)
PA (1) PA8656601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20061113A1 (cg-RX-API-DMAC7.html)
RU (1) RU2007120254A (cg-RX-API-DMAC7.html)
TW (1) TW200637545A (cg-RX-API-DMAC7.html)
WO (1) WO2006065968A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200705103B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984028A2 (en) * 2006-02-14 2008-10-29 Wyeth a Corporation of the State of Delaware Aqueous pharmaceutical formulations of er selective ligands
WO2010105035A2 (en) * 2009-03-11 2010-09-16 University Of South Florida Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
US10149982B2 (en) 2009-03-11 2018-12-11 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
US10758496B2 (en) * 2014-09-02 2020-09-01 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2018183800A1 (en) * 2017-03-30 2018-10-04 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
TR200102992T2 (tr) * 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
JP2004515496A (ja) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
DE60116109T2 (de) * 2001-11-07 2006-09-07 Schering Ag In vitro Screening nach Liganden des Östrogenrezeptors
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
WO2004026290A1 (en) * 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7157492B2 (en) * 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
JP2008505095A (ja) * 2004-07-01 2008-02-21 ワイス エストロゲンリガンドとしての四環式化合物

Also Published As

Publication number Publication date
BRPI0519111A2 (pt) 2008-12-23
CN101321524A (zh) 2008-12-10
AR051844A1 (es) 2007-02-14
WO2006065968A8 (en) 2008-09-12
IL183604A0 (en) 2007-10-31
AU2005316561A1 (en) 2006-06-22
MX2007007347A (es) 2007-07-13
RU2007120254A (ru) 2009-01-27
NO20072658L (no) 2007-09-12
WO2006065968A2 (en) 2006-06-22
PE20061113A1 (es) 2006-11-06
CA2590258A1 (en) 2006-06-22
WO2006065968A3 (en) 2008-04-10
TW200637545A (en) 2006-11-01
GT200500370A (es) 2006-07-13
NI200700152A (es) 2008-06-17
KR20070086329A (ko) 2007-08-27
JP2008524236A (ja) 2008-07-10
EP1824478A2 (en) 2007-08-29
ZA200705103B (en) 2009-11-25
US20060135574A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
ECSP077268A (es) Polimorfo ii de rapamicina y los usos de los mismos
CR6735A (es) Substituted arylpyrazines
PA8577501A1 (es) Inhibidores de quinasas
UY29283A1 (es) Anticuerpos ab(beta)usados en mejorar la cognicion
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
ECSP077280A (es) Moduladores de quinasa de pirrolo-piridina
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
ECSP066467A (es) Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona
CR10444A (es) Anticuerpo humanizado de c-kit
NI200700010A (es) Moduladores de los receptores de alfa 7 acetilcolina nicotinica y sus usos terapéuticos
AR063494A1 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
CR9840A (es) Inhibidores de la pde y combinaciones de los mismos para el tratamiento de trastornos urologicos
PA8566401A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
PA8618901A1 (es) Biaril sulfonamidas y metodo para el uso de las mismas
PT3045474T (pt) Agentes terapêuticos para o tratamento de doenças associadas à proliferação celular indesejada
PT2444424T (pt) Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
PA8619001A1 (es) Biaril sulfonamidas y metodo para el uso de las mismas
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
UY29238A1 (es) Formulaciones de nepafenac para su administracion topica